AU2018203509A1 — Novel crystalline forms of Ibrutinib
Assigned to Apotex Inc · Expires 2019-12-05 · 6y expired
What this patent protects
The present invention provides novel crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-I, a methyl benzoate solvate of 5 lbrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib…
USPTO Abstract
The present invention provides novel crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-I, a methyl benzoate solvate of 5 lbrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib. (Figure 3) C: (n 0 r-c
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.